Author: Healio ophthalmology

OSN talks with Allergan CEO about Pfizer merger, days ahead

The impact of a Pfizer-Allergan merger on the world of U.S. eye care is a matter of speculation.Announced in November 2015, the agreement by the boards of directors of both companies allows for the smaller Ireland-based Allergan to acquire the larger U.S.-based Pfizer, putting Pfizer squarely into the ophthalmic space where it otherwise has a waning presence. The agreement is valued at $160 billion. Allergan’s legacy-rich products, including Restasis (cyclosporine ophthalmic emulsion 0.05%) and Lumigan (bimatoprost ophthalmic solution 0.01%), would bolster Pfizer’s product line.

Ocular surface disease: One physician’s approach to treatment

It has been a busy 2 weeks in the clinic since I wrote my last commentary on dry eye syndrome, focusing on the screening diagnostics I use in my practice. First, a few more thoughts on the diagnosis side, and then on to therapy. I will compare what I do today vs. what I did in the past and focus on what I am really doing in my clinical practice today.In disclosure, I have practiced as a consultative corneal specialist for 38 years, so I may see a different mix (Read more...)

Anti-VEGF treatment may benefit patients with DME, vitreomacular adhesions

Anti-VEGF injections may improve visual outcomes in patients with diabetic macular edema who have vitreomacular adhesions, according to a substudy of READ-3.“VMA does not adversely influence treatment outcomes and therefore should not preclude patients with DME from receiving treatment with anti-VEGF agents,” study author Yasir J. Sepah, MBBS, told Ocular Surgery News.

A thankful beginning to the new year

Happy New Year! How were your holidays? Did your team win its bowl game? How was New Year’s Eve? Did you manage to stay up late enough to see the ball drop? Now, here’s the kicker: How many of your new year’s resolutions have you already blown?I definitely feel you on that last one. So much so that I am going to take an entirely different approach this year and not make any traditional resolutions. Instead I am going to begin my year, both professionally and personally, with a listing (Read more...)

Enrollment completed for PMA arm of first US clinical trial of artificial iris

An artificial iris is available to an increasing number of patients participating in a clinical trial because of a humanitarian use designation granted by the FDA.The CustomFlex artificial iris prosthesis, manufactured by HumanOptics, is designed for patients with iris defects, iris damage and aniridia. The clinical trial’s sponsor, Clinical Research Consultants, plans to submit a premarket approval (PMA) application to the FDA when the trial is completed.

Hardware, software improvements advance OCT capabilities

WAIKOLOA, Hawaii — Hardware improvements that increase scanning speed with more imaging modalities and software enhancements that allow for new scanning protocols are features rounding out the OCT space in 2016, according to a speaker here. “Bottom line is that there are a lot of new things in OCT technology. We haven’t really hit the ceiling,” Jay S. Duker, MD, told colleagues at Retina 2016.